Clinical trials: Episodic Migraine Headache
Migraine, Headache
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
The purpose of this study is to evaluate the safety and efficacy of MK-6096 versus placebo for preventing migraines in participants with episodic migraine.
- Trial name
- NCT01513291
- Testing
- MK-6096
- Volunteers
- 237 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
- Trial name
- NCT03912337
- Testing
- Erenumab
- Where
- 28 sites in United States
- Volunteers
- 29 people
- Sponsor
- Amgen
Migraine
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-2 (NCT02614196)
- Testing
- Galcanezumab
- Where
- 113 sites in United States, Argentina and 10 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo for preventive treatment in Episodic…
- Trial name
- NCT03303092
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 357 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine
Biomarker and Genetic Predictors of Erenumab Treatment Response
To explore the relationship between clinical response to erenumab and genetic biomarkers
- Trial name
- INTERROGATE (NCT04265755)
- Testing
- Erenumab
- Where
- 2 sites in Denmark, Iceland
- Volunteers
- 1,406 people
- Sponsor
- Amgen
Episodic Migraine
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Evidence-based medicine depends on distinguishing between pharmacological effects and placebo effects in randomized controlled trials (RCT).
- Trial name
- NCT00719134
- Testing
- Maxalt
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Beth Israel Deaconess Medical Center
Migraine
Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)
This study investigates whether non-invasive brain stimulation, given for 20 minutes/once per day for ten days (M-F) can reduce migraine pain.
- Trial name
- NCT02964741
- Testing
- Active Comparator
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
- Trial name
- PERSIST (NCT03963232)
- Testing
- Galcanezumab
- Where
- 40 sites in China, India and 1 more
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Episodic Migraine
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
- Trial name
- EMPOwER (NCT03333109)
- Testing
- Erenumab
- Where
- 81 sites in Argentina, India and 9 more
- Volunteers
- 900 people
- Sponsor
- Novartis Pharmaceuticals
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Episodic Migraine
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
- Trial name
- ELEVATE (NCT04740827)
- Testing
- Atogepant 60 mg
- Where
- 114 sites in United States, Australia and 13 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Episodic Migraine
DFN-11 Injection in Episodic Migraine With or Without Aura
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
- Trial name
- RESTOR (NCT02569853)
- Testing
- DFN-11
- Where
- 16 sites in United States
- Volunteers
- 268 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine
Statin/Vitamin D & Migraine Study
The investigators are studying if taking simvastatin and vitamin D together will help prevent episodic migraines. Simvastatin is an FDA approved drug that is typically used to treat high cholesterol and reduce the risk of stroke…
- Trial name
- NCT01225263
- Testing
- Simvastatin, Vitamin D
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Rami Burstein
Migraine
Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks.
- Trial name
- NCT03712917
- Testing
- Greater Occipital Nerve Block, Topiramate, Flunarizine
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Ataturk University
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie